These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3988149)

  • 1. Effect of fenfluramine oral administration on serum prolactin levels in healthy and hyperprolactinemic women.
    Scarduelli C; Mattei AM; Brambilla G; Zavaglia C; Adelasco P; Cavioni V; Ferrari C
    Gynecol Obstet Invest; 1985; 19(2):92-6. PubMed ID: 3988149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition.
    Nicoletti I; Filipponi P; Fedeli L; Gregorini G; Ambrosi F; Sfrappini M; Santeusanio F; Brunetti P
    Horm Metab Res; 1984 Dec; 16(12):658-62. PubMed ID: 6441763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of hypothalamic hyperprolactinemia.
    Ferrari C; Rampini P; Benco R; Caldara R; Scarduelli C; Crosignani PG
    J Clin Endocrinol Metab; 1982 Nov; 55(5):897-901. PubMed ID: 6811605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fenfluramine on growth hormone and prolactin secretion in obese subjects.
    Altomonte L; Zoli A; Alessi F; Ghirlanda G; Manna R; Greco AV
    Horm Res; 1987; 27(4):190-4. PubMed ID: 3436616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of dopamine infusion to suppress the plasma prolactin response to sulpiride in normal and hyperprolactinemic subjects.
    Crosignani PG; Reschini E; Peracchi M; Lombroso GC; Mattei A; Caccamo A
    J Clin Endocrinol Metab; 1977 Oct; 45(4):841-4. PubMed ID: 410826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naloxone reduces the fenfluramine-induced prolactin release in man.
    Foresta C; Scanelli G; Indino M; Federspil G; Scandellari C
    Clin Endocrinol (Oxf); 1985 Apr; 22(4):539-43. PubMed ID: 3987071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin-secreting adenomas in women. VII. Dopamine regulation of prolactin secretion.
    Martin MC; Weiner RI; Monroe SE; Roberts JM; Licko V; Jaffe RB
    J Clin Endocrinol Metab; 1984 Sep; 59(3):485-90. PubMed ID: 6746862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catecholamines and pituitary function. I. Effects of catecholamine synthesis inhibition and subsequent catecholamine infusion on gonadotropin and prolactin serum levels in normal cycling women and in women with hyperprolactinemic amenorrhea.
    Nicoletti I; Filipponi P; Sfrappini M; Fedeli L; Petrelli S; Gregorini G; Santeusanio F; Brunetti P
    Horm Res; 1984; 19(3):158-70. PubMed ID: 6425187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia.
    DeLeo V; Cella SG; Camanni F; Genazzani AR; Müller EE
    Horm Metab Res; 1983 Sep; 15(9):439-43. PubMed ID: 6642414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
    Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fenfluramine and ritanserin on prolactin response to insulin-induced hypoglycemia in obese patients: evidence for failure of the serotoninergic system.
    Bernini GP; Argenio GF; Vivaldi MS; Del Corso C; Sgrò M; Franchi F; Luisi M
    Horm Res; 1989; 31(3):133-7. PubMed ID: 2501208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects.
    Serri O; Kuchel O; Buu NT; Somma M
    J Clin Endocrinol Metab; 1983 Feb; 56(2):255-9. PubMed ID: 6822635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine.
    Quattrone A; Tedeschi G; Aguglia U; Scopacasa F; Direnzo GF; Annunziato L
    Br J Clin Pharmacol; 1983 Nov; 16(5):471-5. PubMed ID: 6639832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin response to the dopamine antagonists sulpiride and domperidone. Further evidence for pituitary dopamine deficiency in hyperprolactinemic disorders of different etiology.
    Ferrari C; Scarduelli C; Rampini P; Brambilla G; Benco R; Pistolesi E; Paracchi A; Mattei A; Boghen M; Crosignani PG
    Gynecol Obstet Invest; 1983; 16(5):299-306. PubMed ID: 6642291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects.
    Sarnacchiaro F; Colao A; Merola B; Di Sarno A; Landi ML; Di Somma C; Ferone D; Tolino A; Lombardi G
    J Endocrinol Invest; 1997 Oct; 20(9):513-8. PubMed ID: 9413804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of erythropoietin administration on prolactin secretion in normal subjects.
    Bernini GP; Mariotti F; Brogi G; Cerri F; Santoni M; Ciardella F; Franchi F
    Nephron; 1993; 65(4):522-6. PubMed ID: 8302403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naloxone does not modify fenfluramine-induced prolactin increase in obese patients.
    Argenio GF; Bernini GP; Vivaldi MS; del Corso C; Santoni R; Franchi F
    Clin Endocrinol (Oxf); 1991 Dec; 35(6):505-8. PubMed ID: 1769132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia.
    Nicoletti I; Filipponi P; Fedeli L; Sfrappini M; Gregorini G; Ambrosi F; Santeusanio F
    Horm Res; 1984; 20(3):202-12. PubMed ID: 6436160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fenfluramine on prolactin secretion in obese patients: evidence for serotoninergic regulation of prolactin in man.
    Barbieri C; Magnoni V; Rauhe WG; Zanasi S; Caldara R; Ferrari C
    Clin Endocrinol (Oxf); 1983 Dec; 19(6):705-10. PubMed ID: 6360431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
    Melis GB; Gambacciani M; Paoletti AM; Beneventi F; Mais V; Baroldi P; Fioretti P
    J Clin Endocrinol Metab; 1987 Sep; 65(3):541-5. PubMed ID: 3624413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.